KEAP1 and nonpapillary renal cell carcinoma: This supports the hypothesis that the KEAP1–Nrf2 pathway plays a significant role in ccRCC subtypes with specific epigenetic changes, suggesting that Nrf2 might be a promising pharmacological target [88].